Positive Phase III data for tofacitinib in ankylosing spondylitis
The AS multicentre, double-blind RCT (n=270) demonstrated that more patients met the primary endpoint, ASAS20 response vs placebo at week 16 (56.4% vs 29.4%; p<0.0001) and ASAS40 response, a secondary endpoint (40.6% vs 12.5%; p<0.0001).
Source:
Biospace Inc.